AI assistant
Cyclerion Therapeutics, Inc. — Director's Dealing 2021
May 10, 2021
35315_dirs_2021-05-10_e746b8b3-5d55-48ec-b312-dac064cd775f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cyclerion Therapeutics, Inc. (CYCN)
CIK: 0001755237
Period of Report: 2021-05-06
Reporting Person: Hecht Peter M (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-05-06 | Common Stock | P | 302000 | $2.43 | Acquired | 1224528 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 485 | Indirect |
| Common Stock | 485 | Indirect |
| Common Stock | 485 | Indirect |
Footnotes
F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.31 to $2.59, inclusive. The reporting person will provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F2: These shares are held in the referenced trust for the benefit of the reporting person's child. The reporting person's spouse is the trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or any other purpose.